ArticleAmerican journal of physiology. Cell physiology2025
Proteomic and functional analysis on endothelial cell heterogeneity identifies key regulators in hyperglycemia-induced dysfunction.
Article in American journal of physiology. Cell physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative Proteogenomics and Single-Cell Transcriptomics Prioritize Candidate Causal Proteins and Therapeutic Targets in Age-Related Macular Degeneration.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Endothelial cells (ECs) play a critical role in managing vascular homeostasis and neovascularization. EC functions vary significantly depending on their anatomic locations, especially for ECs forming macrovascular versus microvascular vessels. ECs possess heterogeneous signaling pathways, energy metabolism, and cellular behaviors that enable them to handle both physiological and hyperglycemic conditions. These variations can impact the efficacy of pharmacotherapy and influence the likelihood of unexpected side effects. In this study, we compared human aortic ECs (HAECs) and human dermal microvascular ECs (HDMVECs) to observe the functional and proteomic differences potentially contributing to EC heterogeneity. Compared with HAECs, HDMVECs exhibited faster proliferation, but lower migration and permeability. Under high glucose (HG), migration was worsened for both cell types, whereas proliferation was unaffected, and permeability increased for HDMVECs. Using proteomic analysis, we identified 126 proteins whose abundance was significantly different between HAECs and HDMVECs. Database for Annotation, Visualization, and Integrated Discovery (DAVID) analysis revealed their biological processes, cellular compartments, molecular functions, and pathways. Under high glucose, WARS1 increased whereas SOD2 decreased. Reversing WARS1 or SOD2 expression levels improved HDMVEC migration and permeability functions. The combined treatment of WARS1 knockdown and SOD2 overexpression fully restored EC migration and reduced permeability to levels comparable with those of their counterparts under normal glucose (NG) conditions. Furthermore, in the cutaneous wound in type 2 diabetic mice, the combination therapy of Wars1 knockdown and SOD2 overexpression accelerated the wound closure and augmented wound angiogenesis. Our studies provide novel molecular insights into EC heterogeneity and identified WARS1 and SOD2 as potential targets for dermal angiogenesis during tissue repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.